Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for neurologists, family medicine/primary care clinicians, internists, obstetricians/gynecologists/women’s health clinicians, psychiatrists, nurses, pharmacists, physician assistants, and other members of the healthcare team for women who may be at risk for Alzheimer’s disease.
The goal of this activity is for members of the healthcare team to be better able to describe the extent to which sex, age at menopause, and hormone therapy use are associated with regional tau at a given level of β-amyloid.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-198-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 5/26/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 5/26/2023
Valid for credit through: 5/26/2024, 11:59 PM EST
processing....
Women vs men with high β-amyloid have greater AD-related neurofibrillary tau tangles, with unclear underlying mechanisms. Premature or early menopause, spontaneous or surgical, occurs in 1% to 10% of women and has been linked to poor outcomes from AD dementia.
Early studies suggested that hormone therapy (HT) use may mitigate cognitive impairment in menopausal or postmenopausal women, but the Women’s Health Initiative (WHI) found that HT use vs placebo was associated with doubled incidence of probable dementia. Subsequent studies of HT have yielded conflicting results.
Early menopause and delayed initiation of HT have been linked to an increase in Alzheimer’s disease (AD) pathology in women, a new imaging study shows.
Investigators found elevated levels of tau protein in the brains of women who initiated HT more than 5 years after menopause onset, whereas those who started the therapy earlier had normal levels.
Tau levels were also higher in women who started menopause before age 45 years, either naturally or after surgery, but only in those who already had high levels of beta-amyloid.
The findings were published online April 3 in JAMA Neurology.[1]
Hotly Debated
Previous research has suggested the timing of menopause and HT initiation may be associated with AD. However, the current research is the first to suggest that tau deposition may explain that link.
“There have been a lot of conflicting findings around whether HT induces risk for Alzheimer’s disease dementia or not, and at least in our hands, our observational evidence suggests that any risk is fairly limited to those rarer cases when women might delay their initiation of HT considerably,” senior investigator Rachel Buckley, PhD, assistant investigator in neurology at Massachusetts General Hospital and an assistant professor of neurology at Harvard Medical School, told Medscape Medical News.
The link between HT, dementia, and cognitive decline has been hotly debated since the initial release of findings from the Women’s Health Initiative Memory Study, reported 20 years ago.[2]
Since then, dozens of studies have yielded conflicting evidence about HT and AD risk, with some showing a protective effect and others showing that the treatment may increase AD risk.[3,4]
For this study, researchers analyzed data from 292 cognitively unimpaired participants (66.1% women) in the Wisconsin Registry for Alzheimer Prevention. About half of the women had received HT.
Women had higher levels of tau measured on positron emission tomography (PET) imaging than age-matched men, even after adjusting for APOE status and other potential confounders.
Higher tau levels were found in those with an earlier age at menopause (P<.001) and HT use (P=.008) compared with men, those with later menopause onset, or those with HT nonuse, but only in patients who also had a higher beta-amyloid burden.
Late initiation of HT (>5 years after age at menopause) was associated with higher tau compared with early initiation (P=.001), regardless of amyloid levels.
Surprising Finding
Although researchers expected to find that surgical history (specifically oophorectomy) might have a greater effect on risk, that was not the case.
“Given that bilateral oophorectomy involves the removal of both ovaries, and the immediate ceasing of estrogen production, I had expected this to be the primary driver of higher tau levels,” Dr Buckley said. “But early age at menopause, regardless of whether the genesis was natural or surgical, seemed to have similar impacts.”
These findings are the latest from Buckley’s group that indicate that women tend to have higher levels of tau than men, regardless of preexisting amyloid burden in the brain.
“We see this in healthy older women, women with dementia and even in postmortem cases,” Dr Buckley said. “It really remains to be seen whether women tend to accumulate tau faster in the brain than men, or whether this is simply a 1-shot phenomenon that we see in observational studies at the baseline.”
“One could really flip this finding on its head and suggest that women are truly resilient to the disease,” she continued. “That is, they can hold much more tau in their brain and remain well enough to be studied, unlike men.”
Among the study’s limitations is that the data were collected at a single point and did not include information on subsequent Alzheimer’s diagnosis or cognitive decline.
“It is important to remember that the participants in this study were not as representative of the general population in the United States, so we cannot extrapolate our findings to women from a range of socioeconomic, racial and ethnic backgrounds or education levels,” she said.
The study’s observational design left researchers unable to demonstrate causation. What is more, the findings also do not support the assertion that hormone therapy may protect against AD, Dr Buckley added.
“I would more confidently say that evidence from our work, and that of many others, seems to suggest that HT initiated around the time of menopause may be benign, not providing benefit or risk, at least in the context of Alzheimer’s disease risk,” she said.
Another important takeaway from the study, Dr Buckley said, is that not all women are at high risk for AD.
“Often the headlines might make you think that most women are destined to progress to dementia, but this simply is not the case,” Dr Buckley said. “We are now starting to really drill down on what might elevate risk for AD in women and use this information to better inform clinical trials and doctors on how best to think about treating these higher-risk groups.”
New Mechanism?
Commenting on the findings for Medscape Medical News, Pauline Maki, PhD, professor of psychiatry, psychology and obstetrics and gynecology at the University of Illinois at Chicago, called the study “interesting.”
“It identifies a new mechanism in humans that could underlie a possible link between sex hormones and dementia,” Dr Maki said.
However, Dr Maki noted that the study was not randomized and that information about menopause onset was self-reported.
“We must remember that many of the hypotheses about hormone therapy and brain health that came from observational studies were not validated in randomized trials, including the hypothesis that hormone therapy prevents dementia,” she said.
The findings do not resolve the debate over hormone therapy and AD risk and point to the need for randomized, prospective studies on the topic, Dr Maki added. Still, she said, they underscore the gender disparity in AD risk.
“It’s a good reminder to clinicians that women have a higher lifetime risk of [AD] and should be advised on factors that might lower their risk,” she said.
The study was funded by the National Institutes of Health. Dr Buckley has disclosed no relevant financial relationships. Dr Maki serves on the advisory boards for Astellas, Bayer, Johnson and Johnson; consults for Pfizer and Mithra; and has equity in Estrigenix, Midi-Health, and Alloy.
JAMA Neuro. Published online April 3, 2023.